CompletedNot Applicable

Influence of Age on Amyloid Load in Alzheimer's Disease and in Atypical Focal Cortical Alzheimer's Disease

France60 participantsStarted 2009-03

Plain-language summary

The first objective is to asses influence of age on amyloid load measured by PET imaging using Pittsburgh B compound (PiB) radio-tracer, in Alzheimer's disease(AD). This will allow the determination of brains age-specific deterioration factors by comparing Early onset AD (EOAD), Late onset AD (LOAD)and atypical focal cortical AD (PCA and LPA). The amount of brain lesions in AD patients is estimated by: 1. measuring the rate of cortical brain atrophy, 2. FDG imaging of glucose metabolism reflecting neuronal activity, and 3. for patients who benefited from a lumbar puncture; Cortical-spinal fluid (CSF) amounts of amyloïd and tau proteins are measured.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * AD patients: clinical dementia rating between 0.5 and 2 free and cued recall test (Grober and Buschke) cued-recall \< 18/48 and total recall \< 40/48 * atypical AD : i visual-spatial disorder and respect of episodic memory progressive evolution, Balint syndrome ii progressive language disorder constituted of logopenic aphasia respect of episodic memory * controls: age over 30 MMSE over or equal to 27 normal neuropsychiatric state for age and education level Exclusion Criteria: * for every patients : psychiatric disorders age under18 absence of social security counter indication to MRI supposed or actual alcoholism or drug addiction pregnancy

What they're measuring

PIB-PET imaging of amyloid load

Timeframe: 0 - 2 months

FDG-PET imaging of glucose metabolism

Timeframe: 0 - 2 months

clinical phenotypic assessment

Timeframe: 0 - 2 months

MRI

Timeframe: 0 - 2 months

ApoE gene sequencing

Timeframe: 0 - 24 months after inclusion

Trial details

NCT IDNCT01095744

SponsorInstitut National de la Santé Et de la Recherche Médicale, France

Sponsor typeOTHER_GOV

Study typeOBSERVATIONAL

Primary completion2012-05

View on ClinicalTrials.gov More Alzheimer's Disease trials

Plain-language summary

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.